Netherlands· NL-6951d909eb4e
Juluca 50 mg/25 mg, filmomhulde tabletten
A dolutegravir and rilpivirine product containing dolutegravir natrium + rilpivirinehydrochloride, registered in Netherlands by ViiV healthcare B.V.. The same ATC class is registered in 13 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Dolutegravir and rilpivirine is registered in 13 of 19 countries.
Countries holding a registration under ATC J05AR21 (dolutegravir and rilpivirine), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 8 of them publish a price we can compare per daily dose
Dolutegravir and rilpivirine · ATC J05AR21
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- DOLUTEGRAVIR NATRIUM + RILPIVIRINEHYDROCHLORIDE
- Manufacturer
- ViiV healthcare B.V.
- Country
- Netherlands (NL)
- ATC code
- J05AR21
- ATC class
- Dolutegravir and rilpivirine
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/18/1282
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Dolutegravir and rilpivirine in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandJulucaAbacus Medicine A/S
- CzechiaJULUCAViiV Healthcare BV, Amersfoort
- United StatesJulucaViiV Healthcare Company
- FranceJULUCA 50 mg/25 mg, comprimé pelliculéVIIV HEALTHCARE (PAYS-BAS)
- CanadaJULUCAVIIV HEALTHCARE ULC
- IcelandJulucaViiV Healthcare BV
- NorwayJulucaViiV Healthcare BV (1)
- PolandJulucaViiV Healthcare BV
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Juluca
- Liechtenstein · Juluca
- Norway · Juluca
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9c49e80e-aaa8-43aa-ac21-6eda4f663b6e GET /v1/drugs/9c49e80e-aaa8-43aa-ac21-6eda4f663b6e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmomhulde tablet",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/juluca-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Dolutegravir and rilpiverine",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp121202",
"excipients": [
"CELLULOSE, MICROKRISTALLIJN (E 460(i))",
"CROSCARMELLOSE NATRIUM (E 468)",
"IJZEROXIDE GEEL (E 172)",
"IJZEROXIDE ROOD (E 172)",
"LACTOSE 1-WATER",
"MACROGOL",
"MAGNESIUMSTEARAAT (E 470b)",
"MANNITOL (D-) (E 421)",
"NATRIUMSTEARYLFUMARAAT",
"NATRIUMZETMEELGLYCOLAAT",
"POLYSORBAAT 20 (E 432)",
"POLYVINYLALCOHOL, GEDEELTELIJK GEHYDROLYSEERD (E1203)",
"POVIDON K 30 (E 1201)",
"SILICIUMDIOXIDE (E 551)",
"TALK (E 553b)",
"TITAANDIOXIDE (E 171)"
],
"substances": [
"DOLUTEGRAVIR NATRIUM",
"RILPIVIRINEHYDROCHLORIDE"
],
"leaflet_url": null,
"authorised_at": "2018/05/16",
"procedure_number": "EMEA/H/C/004427",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/18/1282",
"additional_monitoring": "N"
}See everything about dolutegravir and rilpivirine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.